CCME Global Ltd
₹ 117
-5.00%
11 May
- close price
About
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.
Key Points
- Market Cap ₹ 529 Cr.
- Current Price ₹ 117
- High / Low ₹ 185 / 20.2
- Stock P/E
- Book Value ₹ 6.42
- Dividend Yield 0.00 %
- ROCE 51.6 %
- ROE 51.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Promoter holding has increased by 62.8% over last quarter.
Cons
- Stock is trading at 18.2 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.95% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.23 | |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.23 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | ||||||||
| 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 | |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 106% |
| 3 Years: | 215% |
| TTM: | -35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | % |
| 3 Years: | 122% |
| 1 Year: | 507% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | 52% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | -3.25 | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -4.65 |
| 0.61 | 0.17 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.90 | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 0.16 | |
| Total Liabilities | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| 1.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.18 | 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 | |
| Total Assets | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.98 | -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 | |
| 0.00 | 0.77 | 0.00 | 0.00 | -4.66 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.71 | 4.10 | 2.62 | 0.26 | 3.00 | 0.00 | 0.00 | 0.12 | 0.12 | 0.09 | 0.00 | 0.00 | |
| Net Cash Flow | 5.69 | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Free Cash Flow | 4.98 | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0.00 | 0.00 |
| CFO/OP | -3,112% | 3,240% | 3,771% | 357% | -840% | 9,380% | -10% | 100% | 100% | 64% | 0% | 0% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses INR |
|
||||||||||
| Purchase of Traded Goods INR |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
9h - Submitted Secretarial Compliance Audit Report for FY ended March 31, 2026.
-
Results For The Quarter And Financial Year Ended March 31 2026
24h - Board approved FY26 audited results; 3.225 crore shares allotted via preferential issue raising ₹32.25 crore.
-
Statement Of Deviation For The Quarter And Financial Year Ended March 31, 2026
24h - Quarterly no-deviation report for ₹32.25 crore preferential issue; no funds utilized till 31 March 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 29, 2026
1d - Board approved FY26 audited results and preferential allotment of 3.225 crore shares raising ₹32.25 crore.
-
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On May 29, 2026 To Consider And Approve Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Other Matters
22 May - Board meeting on May 29, 2026 to approve audited Q4 and FY2026 financial results.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1]
a) Aquaculture Probiotic: Proteomix Protein Balanced Gel, Yuccagen Ammonia Controller, Growfast Gen Single Cell Protein, Progutgen Aquaculture Gut Probiotic, Rhodogen PS -Water Probiotic
b) Aqua Feed Supplement: Moultigen Aqua EDTA Aqua Culture, Vitagen C Aqua Culture and Zeo-Gen Multi Mineral Additive Granules from India
c) Aquaculture Water Sanitizer: Sangen- Broad Spectrum Sanitizer
d) Soil Probiotic: Genpro Wat Soil Probiotic
e) Aquaculture: Vibrio Controller In Shrimp Culture